Leta i den här bloggen


fredag 15 mars 2024

ETS-domeenin omaavista transskriptiotekijöistä genominen ja biokemiallinen valaiseva katsaus (Hollenborst PC et al, 2011)

 PMC full text:

Annu Rev Biochem. Author manuscript; available in PMC 2017 Aug 23.
Published in final edited form as:
Annu Rev Biochem. 2011; 80: 437–471.
doi: 10.1146/annurev.biochem.79.081507.103945
Copyright/LicenseRequest permission to reuse

 https://pubmed.ncbi.nlm.nih.gov/21548782/

Review
. 2011:80:437-71.
doi: 10.1146/annurev.biochem.79.081507.103945.

Genomic and biochemical insights into the specificity of ETS transcription factors

Abstract

ETS proteins are a group of evolutionarily related, DNA-binding transcriptional factors. These proteins direct gene expression in diverse normal and disease states by binding to specific promoters and enhancers and facilitating assembly of other components of the transcriptional machinery. The highly conserved DNA-binding ETS domain defines the family and is responsible for specific recognition of a common sequence motif, 5'-GGA(A/T)-3'. Attaining specificity for biological regulation in such a family is thus a conundrum. We present the current knowledge of routes to functional diversity and DNA binding specificity, including divergent properties of the conserved ETS and PNT domains, the involvement of flanking structured and unstructured regions appended to these dynamic domains, posttranslational modifications, and protein partnerships with other DNA-binding proteins and coregulators. The review emphasizes recent advances from biochemical and biophysical approaches, as well as insights from genomic studies that detect ETS-factor occupancy in living cells.

PubMed Disclaimer

 

FUTURE ISSUES

  1. Dynamics are increasingly implicated as a powerful regulatory mechanism in protein function. Studying how intra- and intermolecular interactions establish the amplitude and timescale of these dynamics—and, thus potentially, the DNA-binding properties of transcription factors—is a new avenue for understanding the regulation of gene expression. Biophysical studies of increasing sophistication will help define the physicochemical bases for ETS autoinhibition and dissect the role of dynamics in protein and target DNA recognition by the PNT and ETS domains, respectively.
  2. A high level of redundant genomic occupancy in the ETS family was detected in promoter proximal regions. Further work will determine whether ETS proteins play a redundant mechanistic role in transcription regulation at these targets and whether these sites have functions distinct from more distal enhancer elements.
  3. As genome-wide binding data become available for more ETS proteins, as well as other transcription factors, comparisons will allow classification of redundant, specific, and partially specific binding sites. This categorization will improve the robustness of the new data sets to investigate mechanisms that enable specificity within the ETS family, including composite elements for cooperative binding partnerships and other routes to synergistic transcriptional regulation. Redundancy within subfamilies versus the entire family needs to be clarified.
  4. The ETS genes that are involved in chromosomal abnormalities in solid tumors are limited largely to those in ERG and PEA3 subfamilies. It is not known to what degree the oncogenic functions of these genes overlap. Determining the specific roles of these two subfamilies, compared with the rest of the ETS family, will be important to understanding the mechanisms of ETS-mediated oncogenesis.
  5. The development of therapeutic strategies, including small-molecule modulators of protein interactions, to regulate ETS proteins could have high clinical impact. Currently available and new structural and biochemical information about ETS proteins will be valuable in achieving this challenging research goal.

Inga kommentarer:

Skicka en kommentar